198 related articles for article (PubMed ID: 11966942)
1. Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease.
Bariol C; Meagher AP; Vickers CR; Byrnes DJ; Edwards PD; Hing M; Wettstein AR; Field A
J Gastroenterol Hepatol; 2002 Feb; 17(2):135-9. PubMed ID: 11966942
[TBL] [Abstract][Full Text] [Related]
2. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease.
Bauditz J; Wedel S; Lochs H
Gut; 2002 Feb; 50(2):196-200. PubMed ID: 11788559
[TBL] [Abstract][Full Text] [Related]
4. Endoscopic and Histologic Healing in Children With Inflammatory Bowel Diseases Treated With Thalidomide.
Lazzerini M; Villanacci V; Pellegrin MC; Martelossi S; Magazzù G; Pellegrino S; Lucanto MC; Barabino A; Calvi A; Arrigo S; Lionetti P; Fontana M; Zuin G; Maggiore G; Bramuzzo M; Maschio M; Salemme M; Manenti S; Lorenzi L; Decorti G; Montico M; Ventura A
Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1382-1389.e1. PubMed ID: 28286192
[TBL] [Abstract][Full Text] [Related]
5. Opposite effects of interferon regulatory factor 1 and osteopontin on the apoptosis of epithelial cells induced by TNF-α in inflammatory bowel disease.
Tang R; Yang G; Zhang S; Wu C; Chen M
Inflamm Bowel Dis; 2014 Nov; 20(11):1950-61. PubMed ID: 25208103
[TBL] [Abstract][Full Text] [Related]
6. The clinical implications of thalidomide in inflammatory bowel diseases.
Diamanti A; Capriati T; Papadatou B; Knafelz D; Bracci F; Corsetti T; Elia D; Torre G
Expert Rev Clin Immunol; 2015 Jun; 11(6):699-708. PubMed ID: 25865355
[TBL] [Abstract][Full Text] [Related]
7. Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease.
Ng SC; Arebi N; Kamm MA
Inflamm Bowel Dis; 2007 Feb; 13(2):129-34. PubMed ID: 17206694
[TBL] [Abstract][Full Text] [Related]
8. Systematic review: thalidomide and thalidomide analogues for treatment of inflammatory bowel disease.
Yang C; Singh P; Singh H; Le ML; El-Matary W
Aliment Pharmacol Ther; 2015 Jun; 41(11):1079-93. PubMed ID: 25858208
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results.
Lazzerini M; Martelossi S; Marchetti F; Scabar A; Bradaschia F; Ronfani L; Ventura A
Aliment Pharmacol Ther; 2007 Feb; 25(4):419-27. PubMed ID: 17269997
[TBL] [Abstract][Full Text] [Related]
10. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
[TBL] [Abstract][Full Text] [Related]
11. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America.
; ; Bousvaros A; Antonioli DA; Colletti RB; Dubinsky MC; Glickman JN; Gold BD; Griffiths AM; Jevon GP; Higuchi LM; Hyams JS; Kirschner BS; Kugathasan S; Baldassano RN; Russo PA
J Pediatr Gastroenterol Nutr; 2007 May; 44(5):653-74. PubMed ID: 17460505
[TBL] [Abstract][Full Text] [Related]
12. Morphologic criteria applicable to biopsy specimens for effective distinction of inflammatory bowel disease from other forms of colitis and of Crohn's disease from ulcerative colitis.
Tanaka M; Riddell RH; Saito H; Soma Y; Hidaka H; Kudo H
Scand J Gastroenterol; 1999 Jan; 34(1):55-67. PubMed ID: 10048734
[TBL] [Abstract][Full Text] [Related]
13. [Chronic inflammatory bowel disease: Crohn's disease and ulcerative colitis].
Fiasse R; Denis MA; Dewit O
J Pharm Belg; 2010 Mar; (1):1-9. PubMed ID: 20432590
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum.
Markowitz J; Grancher K; Mandel F; Daum F
Am J Gastroenterol; 1993 Jan; 88(1):44-8. PubMed ID: 8420272
[TBL] [Abstract][Full Text] [Related]
15. Mucosal healing with thalidomide in refractory Crohn's disease patients intolerant of anti-TNF-α drugs: report of 3 cases and literature review.
Scribano ML; Cantoro L; Marrollo M; Cosintino R; Kohn A
J Clin Gastroenterol; 2014 Jul; 48(6):530-3. PubMed ID: 24667589
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
[TBL] [Abstract][Full Text] [Related]
17. Solid Organ Transplantation in Patients with Inflammatory Bowel Diseases (IBD): Analysis of Transplantation Outcome and IBD Activity in a Large Single Center Cohort.
Schnitzler F; Friedrich M; Stallhofer J; Schönermarck U; Fischereder M; Habicht A; Karbalai N; Wolf C; Angelberger M; Olszak T; Beigel F; Tillack C; Göke B; Zachoval R; Denk G; Guba M; Rust C; Grüner N; Brand S
PLoS One; 2015; 10(8):e0135807. PubMed ID: 26288187
[TBL] [Abstract][Full Text] [Related]
18. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
19. Cytokine tumor necrosis factor-alpha A promoter gene polymorphism at position -308 G-->A and pediatric inflammatory bowel disease: implications in ulcerative colitis and Crohn's disease.
Sýkora J; Subrt I; Dìdek P; Siala K; Schwarz J; Machalová V; Varvarovská J; Pazdiora P; Pozler O; Stozický F
J Pediatr Gastroenterol Nutr; 2006 May; 42(5):479-87. PubMed ID: 16707968
[TBL] [Abstract][Full Text] [Related]
20. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine.
Korelitz BI; Mirsky FJ; Fleisher MR; Warman JI; Wisch N; Gleim GW
Am J Gastroenterol; 1999 Nov; 94(11):3248-53. PubMed ID: 10566724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]